Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
![Foto de Cancer Center Clínica Universidad de Navarra (CCUN)](/img/uploaded/C185D7383C9859310EFAE5D78F321270.jpg)
![Foto de University of Bologna](/img/noimage_org.png)
University of Bologna
Bolonia, ItaliaPublicaciones en colaboración con investigadores/as de University of Bologna (90)
2024
-
AI is a viable alternative to high throughput screening: a 318-target study
Scientific Reports, Vol. 14, Núm. 1
-
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
-
Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome
JHEP Reports, Vol. 6, Núm. 7
2023
-
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results
EJHAEM, Vol. 4, Núm. 4, pp. 1117-1131
-
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours
The Lancet Haematology, Vol. 10, Núm. 5, pp. e367-e381
-
Model to predict major complications following liver resection for HCC in patients with metabolic syndrome
Hepatology, Vol. 77, Núm. 5, pp. 1527-1539
2022
-
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis (Advances in Therapy, (2022), 39, 5, (1976-1992), 10.1007/s12325-022-02083-8)
Advances in Therapy
-
Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001))
Annals of Oncology
-
SUCCOR cone study: conization before radical hysterectomy
International Journal of Gynecological Cancer, Vol. 32, Núm. 2, pp. 117-124
-
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project
Journal of Clinical Oncology, Vol. 364
-
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Blood, Vol. 139, Núm. 4, pp. 492-501
-
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
The Lancet, Vol. 399, Núm. 10319, pp. 61-116
-
The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1185-1198
2021
-
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
JHEP Reports, Vol. 3, Núm. 3
-
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
The Lancet Haematology, Vol. 8, Núm. 12, pp. e934-e946
-
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)
British Journal of Cancer
-
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798
-
Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study
Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 66-78